{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:08:52Z","timestamp":1780484932993,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Rheumatische Systemerkrankungen mit interstitieller Lungenerkrankung (SARD-ILD) sind oft mit einer progredienten pulmonalen Fibrose (PPF) assoziiert, die durch eine zunehmende respiratorische Symptomatik, einen fortschreitenden Verlust der Lungenfunktion und eine ung\u00fcnstige Prognose charakterisiert ist. Derzeit verf\u00fcgbare Therapien wie Glukokortikoide, Immunsuppressiva und Antifibrotika k\u00f6nnen den Krankheitsverlauf je nach zugrunde liegender SARD-ILD h\u00e4ufig nur begrenzt beeinflussen, zudem schr\u00e4nken Nebenwirkungen die Therapie ein. Es besteht daher ein erheblicher Bedarf an wirksamen und gut vertr\u00e4glichen Behandlungsoptionen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Dargestellt werden aktuelle Entwicklungen und neue Therapieans\u00e4tze bei SARD-ILD und PPF sowie deren potenzielle Bedeutung f\u00fcr die klinische Praxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>Eine systematische PubMed-Recherche (Publikationen bis Mitte 2025) zu den Begriffen \u201eSARD-ILD\u201c, \u201eCTD-ILD\u201c, \u201ePPF\u201c und \u201eTreatment\u201c identifizierte relevante Studien zu neuen Behandlungsans\u00e4tzen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Zu den derzeit in klinischer Entwicklung befindlichen Substanzen z\u00e4hlen u.\u00a0a. Nerandomilast, Belimumab, Admilparant, Anifrolumab sowie inhalatives Treprostinil. Nerandomilast, ein pr\u00e4ferentieller PDE4B-Inhibitor mit immunmodulatorischen, vaskul\u00e4ren und antifibrotischen Eigenschaften, reduzierte in der Phase-3-Studie FIBRONEER-ILD den Lungenfunktionsverlust und das Mortalit\u00e4tsrisiko bei guter Vertr\u00e4glichkeit und k\u00f6nnte damit einen Wendepunkt im therapeutischen Management autoimmunassoziierter ILD darstellen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Innovative therapeutische Perspektiven f\u00fcr die SARD-ILD und PPF sind durch erfolgversprechende Arzneimittelstudien gegeben und k\u00f6nnten in Zukunft die Prognose und erhebliche Krankheitslast der Betroffenen merklich verbessern.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-026-01807-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:21:58Z","timestamp":1774452118000},"page":"382-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management von SARD-ILD im Wandel","Evolving management of SARD-ILD"],"prefix":"10.1007","volume":"85","author":[{"given":"Torsten","family":"Witte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Schupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005086","volume":"11","author":"Y Allanore","year":"2025","unstructured":"Allanore\u00a0Y, Vonk\u00a0MC, Distler\u00a0O et\u00a0al (2025) Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3\u2011year data from SENSCIS-ON. RMD Open 11:e005086. https:\/\/doi.org\/10.1136\/rmdopen-2024-005086","journal-title":"RMD Open"},{"key":"1807_CR2","doi-asserted-by":"publisher","unstructured":"Antoniou\u00a0KM, Distler\u00a0O, Gheorghiu\u00a0AM et\u00a0al (2025) ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir\u00a0J 2500896. https:\/\/doi.org\/10.1183\/13993003.02533-2024","DOI":"10.1183\/13993003.02533-2024"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr\u00a0J, Prasse\u00a0A, Kreuter\u00a0M et\u00a0al (2021) Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 9:476\u2013486. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3","journal-title":"Lancet Respir Med"},{"key":"1807_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M et\u00a0al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"1807_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V et\u00a0al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N\u00a0Engl J Med 381:1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"1807_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02571-2021","volume":"60","author":"N Hambly","year":"2022","unstructured":"Hambly\u00a0N, Farooqi\u00a0MM, Dvorkin-Gheva\u00a0A et\u00a0al (2022) Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir\u00a0J 60:2102571. https:\/\/doi.org\/10.1183\/13993003.02571-2021","journal-title":"Eur Respir J"},{"key":"1807_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","volume":"13","author":"FE Herrmann","year":"2022","unstructured":"Herrmann\u00a0FE, Hesslinger\u00a0C, Wollin\u00a0L, Nickolaus\u00a0P (2022) BI 1015550 is a\u00a0PDE4B Inhibitor and a\u00a0Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol 13:838449. https:\/\/doi.org\/10.3389\/fphar.2022.838449","journal-title":"Front Pharmacol"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ard.2025.05.390","volume":"84","author":"AM Hoffmann-Vold","year":"2025","unstructured":"Hoffmann-Vold\u00a0AM, Assassi\u00a0S, Cottin\u00a0V et\u00a0al (2025) LB0003 Efficacy and safety of nerandomilast in patients with autoimmune disease\u2013related progressive pulmonary fibrosis: subgroup analysis of the FIBRONEER-ILD trial. Ann Rheum Dis 84:315\u2013316. https:\/\/doi.org\/10.1016\/j.ard.2025.05.390","journal-title":"Ann Rheum Dis"},{"key":"1807_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE et\u00a0al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"key":"1807_CR10","unstructured":"Khanna D, Spino C, Bernstein E et\u00a0al. (2022) Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III [abstract]. Arthritis Rheumatol 74 (suppl\u00a09). https:\/\/acrabstracts.org\/abstract\/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-alone-results-from-the-scleroderma-lung-study-iii\/. Accessed October\u00a015, 2025."},{"key":"1807_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb\u00a0M, Crestani\u00a0B, Maher\u00a0TM (2023) Phosphodiesterase\u00a04B inhibition: a\u00a0potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev 32:220206. https:\/\/doi.org\/10.1183\/16000617.0206-2022","journal-title":"Eur Respir Rev"},{"key":"1807_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","volume":"80","author":"M Kou","year":"2024","unstructured":"Kou\u00a0M, Jiao\u00a0Y, Li\u00a0Z et\u00a0al (2024) Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol 80:1445\u20131460. https:\/\/doi.org\/10.1007\/s00228-024-03720-7","journal-title":"Eur J Clin Pharmacol"},{"key":"1807_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher\u00a0TM (2024) Interstitial Lung Disease: A Review. JAMA 331:1655\u20131665. https:\/\/doi.org\/10.1001\/jama.2024.3669","journal-title":"JAMA"},{"key":"1807_CR14","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher\u00a0TM, Assassi\u00a0S, Azuma\u00a0A et\u00a0al (2025) Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N\u00a0Engl J Med 392:2203\u20132214. https:\/\/doi.org\/10.1056\/NEJMoa2503643","journal-title":"N Engl J Med"},{"key":"1807_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00240-2022","volume":"8","author":"TM Maher","year":"2022","unstructured":"Maher\u00a0TM, Schlecker\u00a0C, Luedtke\u00a0D et\u00a0al (2022) Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis. ERJ Open Res 8:00240\u201302022. https:\/\/doi.org\/10.1183\/23120541.00240-2022","journal-title":"ERJ Open Res"},{"key":"1807_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher\u00a0TM, Tudor\u00a0VA, Saunders\u00a0P et\u00a0al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11:45\u201354. https:\/\/doi.org\/10.1016\/S2213-2600(22)00359-9","journal-title":"Lancet Respir Med"},{"key":"1807_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1586197","volume":"16","author":"S Majewski","year":"2025","unstructured":"Majewski\u00a0S, G\u00f3rska\u00a0K, Lewandowska\u00a0KB et\u00a0al (2025) Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland. Front Pharmacol 16:1586197. https:\/\/doi.org\/10.3389\/fphar.2025.1586197","journal-title":"Front Pharmacol"},{"key":"1807_CR18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1093\/rheumatology\/kead491","volume":"63","author":"K Morrisroe","year":"2024","unstructured":"Morrisroe\u00a0K, Hansen\u00a0D, Stevens\u00a0W et\u00a0al (2024) Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease. Rheumatol Oxf Engl 63:1874\u20131881. https:\/\/doi.org\/10.1093\/rheumatology\/kead491","journal-title":"Rheumatol Oxf Engl"},{"key":"1807_CR19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","volume":"9","author":"SD Nathan","year":"2021","unstructured":"Nathan\u00a0SD, Waxman\u00a0A, Rajagopal\u00a0S et\u00a0al (2021) Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med 9:1266\u20131274. https:\/\/doi.org\/10.1016\/S2213-2600(21)00165-X","journal-title":"Lancet Respir Med"},{"key":"1807_CR20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu\u00a0G, Remy-Jardin\u00a0M, Richeldi\u00a0L et\u00a0al (2022) Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205:e18\u2013e47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"1807_CR21","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1111\/bph.17303","volume":"181","author":"D Reininger","year":"2024","unstructured":"Reininger\u00a0D, Fundel-Clemens\u00a0K, Mayr\u00a0CH et\u00a0al (2024) PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells. Br J Pharmacol 181:4766\u20134781. https:\/\/doi.org\/10.1111\/bph.17303","journal-title":"Br J Pharmacol"},{"key":"1807_CR22","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3224","volume":"209","author":"D Reininger","year":"2024","unstructured":"Reininger\u00a0D, Wolf\u00a0F, Mayr\u00a0Ch et\u00a0al (2024) Staying in the Flow: Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) Improves Features of Vascular Dysfunction in Lung Fibrosis In Vitro and In Vivo. Am J Respir Crit Care Med 209:A3224. https:\/\/doi.org\/10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3224","journal-title":"Am J Respir Crit Care Med"},{"key":"1807_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.3069","volume":"83","author":"D Schniertshauer","year":"2024","unstructured":"Schniertshauer\u00a0D, Ebenezer\u00a0DL, Schloesser\u00a0D et\u00a0al (2024) The preferential PDE4B inhibitor BI 1015550 exhibits antifibrotic and anti-inflammatory effects in human in vitro SSc models. Ann Rheum Dis 83:1911. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.3069","journal-title":"Ann Rheum Dis"},{"key":"1807_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon\u00a0JJ, Danoff\u00a0SK, Woodhead\u00a0FA et\u00a0al (2023) Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med 11:87\u201396. https:\/\/doi.org\/10.1016\/S2213-2600(22)00260-0","journal-title":"Lancet Respir Med"},{"key":"1807_CR25","doi-asserted-by":"publisher","first-page":"00145","DOI":"10.1183\/23120541.00145-2020","volume":"7","author":"J Swigris","year":"2021","unstructured":"Swigris\u00a0J, Cutts\u00a0K, Male\u00a0N et\u00a0al (2021) The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res 7:145\u20132020. https:\/\/doi.org\/10.1183\/23120541.00145-2020","journal-title":"ERJ Open Res"},{"key":"1807_CR26","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin\u00a0DP, Elashoff\u00a0R, Clements\u00a0PJ et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"1807_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ et\u00a0al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01807-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:29:04Z","timestamp":1780482544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01807-3"}},"subtitle":["Aktuelle Herausforderungen und neue Therapieoptionen mit Rheuma-assoziierten interstitiellen Lungenerkrankungen","Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases"],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01807-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Witte: Berater- und Vortragshonorare von AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, Fresenius Kabi, Galapagos, GSK, Janssen, Lilly, Medac, Nordic, Novartis, Sanofi und UCB; Reisekosten\u00fcbernahme von AbbVie, Janssen, Lilly und UCB. J.\u00a0Schupp: Berater- und Vortragshonorare von Boehringer Ingelheim, Merck\/MSD, GSK, AOP Health und Kinevant; Reisekosten\u00fcbernahme von Boehringer Ingelheim; Forschungsf\u00f6rderung durch die Ann Theodore Foundation, die Deutsche Forschungsgemeinschaft (DFG), die Fritz-Thyssen-Stiftung, die Else Kr\u00f6ner-Fresenius-Stiftung, das Nieders\u00e4chsische Ministerium f\u00fcr Wissenschaft und Kultur sowie das Deutsche Zentrum f\u00fcr Lungenforschung; Honorar f\u00fcr Gutachtert\u00e4tigkeiten von der Ann Theodore Foundation; Patentanmeldungen bzw. -inhaberschaften: EP-3964214-A1\/US12036218B2.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}